Frontlight ResearchEarly access
Myelodysplastic syndromes trials in Germany
25 of 28 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peoplePhase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
- Where
- Arnsberg, Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Bremen, Brunswick, Darmstadt, Dortmund, Frankfurt Am Main, Giessen, Goch, Greifswald, Halle (Saale), Hamburg, Hamm, Hannover, Hanover, Heilbronn, Herne, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Ludwigshafen Am Rhein, Magdeburg, Mainz, Minden, Munich, Offenburg, Oldenburg, Regensburg, Rostock, Stuttgart, Traunstein, Trier, Tuebingen, Ulm, Villingen-Schwenningen, Wuppertal
- Age
- 18 years to 75 years
- People
- 650 worldwide
- Run by
- University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00 - Phase 2Taking peopleVenetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
- Where
- Tuebingen
- Age
- 18 years to 75 years
- People
- 27
- Run by
- University Hospital Tuebingen
See details and how to joinNCT07214064 · EU 2025-521372-62-00 - Phase 1Not yet taking people in GermanyA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Berlin, Munich, Ulm
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 - Phase 3Taking peopleA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Where
- Berlin, Bonn, Duesseldorf, Halle (Saale), Leipzig, Magdeburg
- Age
- 18 years and over
- People
- 225 worldwide
- Run by
- Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00 - Phase 3Not yet taking people in GermanyA Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
- Where
- Bayreuth, Berlin, Halle (Saale), Muenster
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00 - Phase 1/2Taking peopleStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm
- Age
- 16 years and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00 - Phase 2Active, not recruitingA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Where
- Bayreuth, Berlin, Bonn, Duesseldorf, Esslingen am Neckar, Halle (Saale), Mainz
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- Takeda
See details and how to joinNCT04419649 · EU 2023-507469-24-00 - Phase 1/2Taking peopleAZALOX Study: Safety and Efficacy of PXS-5505 with 5-Azacitidine in MDS and CMML Patients
- Where
- Bonn, Dresden, Duesseldorf, Goettingen, Hanover, Luebeck, Mainz, Mannheim, Munich, Oldenburg
- Age
- 18 years and over
- People
- 42
- Run by
- Heidelberg University
See details and how to join2024-517237-40-00 - Phase 2Active, not recruitingA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
- Where
- Dresden, Düsseldorf, Hamburg, Lübeck, Munich, Tübingen
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00 - Phase 3Taking peopleLisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- Where
- Berlin, Dresden, Duesseldorf, Halle (Saale), Leipzig, Stuttgart, Ulm
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00 - Phase 2/3Taking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg
- Age
- 18 years and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - Phase 4Taking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
- Age
- 18 years and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 - Phase 1/2Taking peopleVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- Where
- Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich
- Age
- 18 years and over
- People
- 38
- Run by
- Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05807932 · EU 2024-514688-24-00 - Phase 2Active, not recruiting(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Aachen, Freiburg im Breisgau, Lübeck, Mannheim
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 1/2Taking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Leipzig, Ulm
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - Phase 3Taking peopleIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Where
- Dresden, Duesseldorf, Goettingen, Hanover, Leipzig, Munich
- Age
- 18 years and over
- People
- 48 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00 - Phase 2Taking peopleEvaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
- Where
- Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald, Halle, Jena, Kiel, Leipzig, Mainz, Münster, Nuremberg, Rostock, Stuttgart
- Age
- 18 years and over
- People
- 220
- Run by
- Technische Universität Dresden
See details and how to joinNCT07025824 - Phase 2Taking peopleProspective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
- Where
- Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mainz, Mannheim, Muenster, Munich, Oldenburg, Rostock, Ulm
- Age
- 18 years to 75 years
- People
- 76
- Run by
- Technische Universität Dresden
See details and how to joinNCT06717958 · EU 2023-509055-14-00 - Phase 2CompletedA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Brunswick, Luebeck
- Age
- 18 years and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - Phase 1/2Not yet taking people in GermanyA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
- Where
- Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00 - Phase 3CompletedA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, München
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 2Taking peopleA Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- Where
- Dresden, Leipzig, Luebeck, Mainz, Muenster, Munich
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06847867 · EU 2024-519928-24-00 - Phase 1/2SuspendedAB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Chemnitz, Halle (Saale), Leipzig
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- AB Science
See details and how to joinNCT05211570 · EU 2024-516641-39-00 - Phase 1/2CompletedClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Berlin, Brunswick, Leipzig
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00 - Phase 2Taking peopleEfficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
- Where
- Berlin, Bonn, Cottbus, Erlangen, Greifswald, Hamburg, Kassel, Koblenz, Landshut, Leipzig, Mannheim, Meschede, Mönchengladbach, München, Münster, Oberhausen, Rostock, Saarbrücken, Trier, Tübingen
- Age
- 18 years and over
- People
- 213
- Run by
- University of Leipzig
See details and how to joinNCT05384691